A Study of Imlifidase in Patients With Guillain-Barré Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

February 27, 2024

Study Completion Date

February 27, 2024

Conditions
Guillain-Barré Syndrome (GBS)
Interventions
DRUG

Imlifidase

All subjects will receive imlifidase (Day 1) prior to standard care IVIg

Trial Locations (11)

13385

Hôpital de la Timone - Centre de référence des maladies neuromusculaires et de la SLA, Marseille

33076

CHU Bordeaux - Hôpital Pellegrin Tripode, Bordeaux

34295

CHU de Montpellier, Hôpital Gui de Chauliac, Montpellier

44093

Centre Hospitalier Universitaire de Nantes, Nantes

87000

CHU de Limoges - Hôpital Dupuytren, Limoges

94270

CHU Le Kremlin-Bicêtre. Service Neurologie, Le Kremlin-Bicêtre

67 098

Service de neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg

Unknown

Amsterdam UMC, Amsterdam

Queen Elizabeth University Hospital Glasgow, Glasgow

Oxford University Hospital, Oxford

3015 GD

Erasmus Medical Centre, Rotterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hansa Biopharma AB

INDUSTRY

NCT03943589 - A Study of Imlifidase in Patients With Guillain-Barré Syndrome | Biotech Hunter | Biotech Hunter